These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Winnes M; Lissbrant E; Damber JE; Stenman G Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040 [TBL] [Abstract][Full Text] [Related]
4. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517 [TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811 [TBL] [Abstract][Full Text] [Related]
6. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer]. Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766 [TBL] [Abstract][Full Text] [Related]
7. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128 [TBL] [Abstract][Full Text] [Related]
8. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300 [TBL] [Abstract][Full Text] [Related]
9. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. Teixeira MR Am J Surg Pathol; 2008 Apr; 32(4):642-4; author reply 644. PubMed ID: 18317354 [No Abstract] [Full Text] [Related]
10. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Zhang S; Pavlovitz B; Tull J; Wang Y; Deng FM; Fuller C Diagn Mol Pathol; 2010 Sep; 19(3):151-6. PubMed ID: 20736744 [TBL] [Abstract][Full Text] [Related]
11. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963 [TBL] [Abstract][Full Text] [Related]
13. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214 [TBL] [Abstract][Full Text] [Related]
14. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Wang J; Cai Y; Ren C; Ittmann M Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141 [TBL] [Abstract][Full Text] [Related]
15. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Yoshimoto M; Ludkovski O; Bayani J; Graham C; Zielenska M; Squire JA Genes Chromosomes Cancer; 2007 Sep; 46(9):861-3. PubMed ID: 17584912 [No Abstract] [Full Text] [Related]
16. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Shah RB Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797 [TBL] [Abstract][Full Text] [Related]
17. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens]. Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Mehra R; Han B; Tomlins SA; Wang L; Menon A; Wasco MJ; Shen R; Montie JE; Chinnaiyan AM; Shah RB Cancer Res; 2007 Sep; 67(17):7991-5. PubMed ID: 17804708 [TBL] [Abstract][Full Text] [Related]
19. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Lee K; Chae JY; Kwak C; Ku JH; Moon KC Urology; 2010 Nov; 76(5):1268.e7-13. PubMed ID: 20800881 [TBL] [Abstract][Full Text] [Related]
20. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]